D COLLEN RES FOUNDATION VZW has a total of 25 patent applications. Its first patent ever was published in 2000. It filed its patents most often in Canada, EPO (European Patent Office) and Australia. Its main competitors in its focus markets pharmaceuticals, biotechnology and agriculture are NOVOZYMES BIOPHARMA DK AS, UNIV SHANGHAI 2ND MEDICAL and SIBTECH INC.
# | Country | Total Patents | |
---|---|---|---|
#1 | Canada | 6 | |
#2 | EPO (European Patent Office) | 5 | |
#3 | Australia | 4 | |
#4 | WIPO (World Intellectual Property Organization) | 4 | |
#5 | United States | 3 | |
#6 | United Kingdom | 2 | |
#7 | Norway | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Biotechnology | |
#3 | Agriculture | |
#4 | Measurement |
# | Technology | |
---|---|---|
#1 | Medical preparations | |
#2 | Therapeutic chemical compounds | |
#3 | Peptides | |
#4 | Microorganisms | |
#5 | Animal care | |
#6 | Analysing materials |
# | Name | Total Patents |
---|---|---|
#1 | Collen Desire | 8 |
#2 | Carmeliet Peter | 8 |
#3 | Saint-Remy Jean-Marie R | 8 |
#4 | Jacquemin Marc G | 8 |
#5 | Saint-Remy Jean-Marie | 3 |
#6 | Jacquemin Marc | 3 |
#7 | Gilles Jean-Guy G | 3 |
#8 | Moons Lieve | 2 |
#9 | Van Linthout Sophie | 1 |
#10 | Van Geet Chris | 1 |
Publication | Filing date | Title |
---|---|---|
CA2585056A1 | Use of survivin to treat kidney failure | |
EP1583550A2 | Inhibition of pacap signalling for the prevention and treatment of thrombocytopenia | |
WO2004046363A1 | Induced humoral immune response using promoters specifically active in antigen presenting cells | |
GB0319345D0 | Variable antibodies | |
GB0319118D0 | Variable antibodies | |
US7105168B1 | Method of improving ischemic muscle function by administering placental growth factor | |
EP1388544A1 | Anti-idiotypic antibodies against factor VIII inhibitor and uses thereof | |
WO02096454A1 | Recombinant molecules with reduced immunogenicity, methods and intermediates for obtaining them and their use in pharmaceutical compositions and diagnostic tools |